PXD101, a non-specific HDAC inhibitor (pan-HDACi), was proven to be effective and well-tolerated in patients with peripheral T-cell lymphoma (PTCL) or cutaneous T-cell lymphoma (CTCL) in a multicenter study 22. This evidence concerns the gene HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma.